ARTHROTEC 50

Compare ARTHROTEC 50  to:
Compare
Compare

Generic Name for ARTHROTEC 50

Diclofenac sodium 50mg (e-c), misoprostol 200micrograms; tabs.

Legal Classification:

Rx

Pharmacological Class for ARTHROTEC 50

NSAID + prostaglandin E1 analogue.

Manufacturer of ARTHROTEC 50

Pfizer Labs

Indications for ARTHROTEC 50

Osteoarthritis (OA) or rheumatoid arthritis (RA) in patients at high risk for developing NSAID-induced gastric or duodenal ulcers.

Adult dose for ARTHROTEC 50

Swallow whole; food may reduce diarrhea. ≥18yrs: OA: one Arthrotec 50 tab 3 times daily. RA: one Arthrotec 50 tab 3–4 times daily. Both: if not tolerated, may reduce to one Arthrotec 50 or one Arthrotec 75 tablet twice daily (this may be less effective in preventing ulcers). See literature.

Children's dosing for ARTHROTEC 50

<18yrs: not recommended.

Also:

Contraindications for ARTHROTEC 50

Pregnancy (Cat.X). Aspirin allergy. Coronary artery bypass graft surgery.

Warnings/Precautions for ARTHROTEC 50

For women of childbearing potential: obtain negative serum pregnancy test within 2 weeks before start of therapy; begin Arthrotec therapy on 2nd or 3rd day of menstrual period; maintain contraception during therapy; give oral and written warnings on risks in pregnancy. History of ulcer disease or GI bleeding. Inflammatory bowel disease. Cardiovascular disease. Edema. Heart failure. Hypertension. Asthma. Hepatic or renal dysfunction. Monitor CBCs, blood chemistry, hepatic and renal function. Check ALT (SGPT) within 4–8 wks then periodically. Discontinue if signs/symptoms of liver or renal disease develop, or if abnormal liver function tests persist or worsen. Hepatic porphyria. Dehydration. SLE. Elderly. Debilitated. Labor & delivery. Nursing mothers: not recommended.

Interactions for ARTHROTEC 50

Avoid magnesium-containing antacids, salicylates, aspirin, other NSAIDs. May antagonize ACE-inhibitors, diuretics. Digoxin, methotrexate, cyclosporine, lithium, warfarin toxicity. Hyper- or hypoglycemia possible with insulin, oral hypoglycemic agents. Increased risk of GI bleed with oral corticosteroids, anticoagulants (monitor), alcohol, smoking, prolonged NSAID therapy. Increased serum potassium with K+-sparing diuretics.

Adverse Reactions for ARTHROTEC 50

Abdominal pain, diarrhea, dyspepsia, nausea, flatulence, GI bleed/ulcer, other GI disturbances, rash (may be serious, eg, Stevens Johnson Syndrome; discontinue if occurs), elevated transaminase levels, anemia; anaphylactic reactions, aseptic meningitis (rare). See literature re: risk of cardiovascular events.

How is ARTHROTEC 50 supplied?

Arthrotec 50—60, 90
Arthrotec 75—60

Related Disease:

Arthritis~NSAIDs
Rheumatoid arthritis

Related Resources

Arava Boxed Warning updated to include severe liver injury

July 13, 2010

The FDA has updated the Boxed Warning of Arava (leflunomide, from sanofi aventis) to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced.

Phase 3 study of Lodotra for the treatment of rheumatoid arthritis (RA)

June 17, 2010

Horizon Pharma announced that data from its Phase 3 study of Lodotra showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

Phase 3 trial of Lodotra for rheumatoid arthritis

June 16, 2010

Horizon Pharma announced positive results from its Phase 3 registration study of Lodotra (prednisone tablet), that showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Salonpas Pain Relief Patch and Salonpas Arthritis Pain patch available

May 24, 2010

Hisamitsu announced the launch of Salonpas Pain Relief Patch (10% methyl salicylate and 3% I-menthol) and Salonpas Arthritis Pain patch (10% methyl salicylate and 3% I-menthol) for the temporary relief of mild to moderate aches and pains of the muscles and joints associated with arthritis, sprains, strains, bruises and simple backaches experienced by patients age ≥18 years.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions